comparemela.com

Latest Breaking News On - Vascular biogenic - Page 1 : comparemela.com

Head to Head Comparison: Catalent (NYSE:CTLT) & Vascular Biogenics (NASDAQ:VBLT)

Catalent (NYSE:CTLT – Get Free Report) and Vascular Biogenics (NASDAQ:VBLT – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership. Analyst Recommendations This is a breakdown of recent recommendations […]

Reviewing Catalent (NYSE:CTLT) and Vascular Biogenics (NASDAQ:VBLT)

Catalent (NYSE:CTLT – Get Free Report) and Vascular Biogenics (NASDAQ:VBLT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends. Institutional & Insider Ownership 1.0% of Vascular Biogenics shares […]

Vascular Biogenics Ltd (NASDAQ:VBLT) Expected to Post Quarterly Sales of $160,000 00

Wall Street analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) to post $160,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vascular Biogenics’ earnings. The highest sales estimate is $200,000.00 and the lowest is $100,000.00. Vascular Biogenics posted sales of $190,000.00 during the same quarter […]

-$0 13 EPS Expected for Vascular Biogenics Ltd (NASDAQ:VBLT) This Quarter

Analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) to announce ($0.13) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vascular Biogenics’ earnings, with estimates ranging from ($0.14) to ($0.12). Vascular Biogenics posted earnings of ($0.12) per share in the same quarter last year, which […]

Brokerages Expect Vascular Biogenics Ltd (NASDAQ:VBLT) Will Announce Quarterly Sales of $200,000 00

Wall Street analysts expect Vascular Biogenics Ltd. (NASDAQ:VBLT – Get Rating) to report $200,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Vascular Biogenics’ earnings. The lowest sales estimate is $190,000.00 and the highest is $200,000.00. Vascular Biogenics reported sales of $190,000.00 during the same quarter last year, which […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.